Aptevo Therapeutics Announces Closing of $8M Offering Priced At-the-Market Under Nasdaq Rules

Aptevo Therapeutics has raised approximately $8M through a registered direct offering to support the continued clinical development of its cancer immunotherapy candidates. The offering included common stock and warrants, with Roth Capital Partners acting as the placement agent. Proceeds will be used for advancing pipeline programs, as well as for working capital and general corporate purposes.